Skip to content

The effect of adding IMOD Iranian drug in HIV-positive patients

The Effect of Adjuvant IMOD therapy on the Immunological Status of HIV-positive Patients: A Random Controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015070423046N1
Enrollment
60
Registered
2015-09-10
Start date
2013-08-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS. Human immunodeficiency virus [HIV] disease

Interventions

Intervention 1: Intervention group: patients underwent IMOD infusion in addition to HAART therapy. IMOD vials contain 120 mg in 4 cc. It was diluted in 50 to 100 ml of 5% dextrose and administrated wi
Treatment - Drugs
Control group: The HAART regimen that includes 1 NNRTI + 2 NRTI. *nucleoside reverse transcriptase inhibitors (NRTIs) **non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Intervention group: patients underwent IMOD infusion in addition to HAART therapy. IMOD vials contain 120 mg in 4 cc. It was diluted in 50 to 100 ml of 5% dextrose and administrated within half an ho

Sponsors

Vice chancellor for research Of Qom Branch Of Islamic Azad University - Counseling Center for Behavi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: HIV-positive patients (with two positive ELISA tests and a positive Western blot test) with Indications for treatment with HAART regimen Exclusion criteria: The patient withdrew from the study of cooperation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
CD4 (cluster of differentiation 4). Timepoint: Before and after the interventions(After 90 days). Method of measurement: Flow cytometry.;TLC ( Total lymphocyte count ). Timepoint: Before and after the interventions(After 90 days). Method of measurement: CBC Diff.

Secondary

MeasureTime frame
BUN , Cr. Timepoint: Before and after the interventions(After 90 days). Method of measurement: Routine laboratory scale measurements.;Liver function tests (LFT). Timepoint: Before and after the interventions(After 90 days). Method of measurement: Routine laboratory scale measurements.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Gholamzadeh Baees

Qom Branch Of Islamic Azad University

Dr.M.Gholamzadeh@Gmail.com; Mehdi_Mephisto@yahoo.com+98 25 3778 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026